USA Financial Formulas Buys New Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

by · The Markets Daily

USA Financial Formulas bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 643 shares of the medical instruments supplier’s stock, valued at approximately $60,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC raised its holdings in LeMaitre Vascular by 0.4% in the second quarter. Conestoga Capital Advisors LLC now owns 1,941,501 shares of the medical instruments supplier’s stock valued at $159,747,000 after acquiring an additional 8,584 shares in the last quarter. Vanguard Group Inc. raised its holdings in LeMaitre Vascular by 0.3% during the first quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after purchasing an additional 4,964 shares in the last quarter. Congress Asset Management Co. MA raised its holdings in LeMaitre Vascular by 12.0% during the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after purchasing an additional 71,411 shares in the last quarter. Driehaus Capital Management LLC raised its holdings in LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares in the last quarter. Finally, Summit Creek Advisors LLC raised its holdings in LeMaitre Vascular by 0.6% during the first quarter. Summit Creek Advisors LLC now owns 229,936 shares of the medical instruments supplier’s stock worth $15,259,000 after purchasing an additional 1,435 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective on the stock. JMP Securities raised their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Barrington Research reissued an “outperform” rating and set a $92.00 price objective on shares of LeMaitre Vascular in a report on Friday, September 20th. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.40.

Check Out Our Latest Stock Analysis on LMAT

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,275 shares of company stock worth $2,598,150 in the last three months. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Down 3.9 %

Shares of LMAT opened at $89.28 on Friday. The firm has a market cap of $2.01 billion, a PE ratio of 53.46, a price-to-earnings-growth ratio of 2.45 and a beta of 0.88. The company’s 50 day simple moving average is $87.88 and its 200-day simple moving average is $80.32. LeMaitre Vascular, Inc. has a 12-month low of $44.27 and a 12-month high of $93.32.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the firm posted $0.37 earnings per share. As a group, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were given a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.72%. LeMaitre Vascular’s dividend payout ratio (DPR) is 38.32%.

About LeMaitre Vascular

(Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Further Reading

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report).